In vitro and in vivo interaction between cisplatin and topotecan in ovarian carcinoma systems.
about
Dose and schedule-finding study of oral topotecan and weekly cisplatin in patients with recurrent ovarian cancerBCL2 and CASP8 regulation by NF-kappaB differentially affect mitochondrial function and cell fate in antiestrogen-sensitive and -resistant breast cancer cells.A phase I study of paclitaxel, topotecan, cisplatin and Filgrastim in patients with newly diagnosed advanced ovarian epithelial malignancies: a Gynecologic Oncology Group study.Plasma and cerebrospinal fluid pharmacokinetics of topotecan in a phase I trial of topotecan, tamoxifen, and carboplatin, in the treatment of recurrent or refractory brain or spinal cord tumors.Co-inhibition of BCL-W and BCL2 restores antiestrogen sensitivity through BECN1 and promotes an autophagy-associated necrosis.A RXR ligand 6-OH-11-O-hydroxyphenanthrene with antitumour properties enhances (-)-epigallocatechin-3-gallate activity in three human breast carcinoma cell lines.Synergy of karenitecin and mafosfamide in pediatric leukemia, medulloblastoma, and neuroblastoma cell linesMYC regulates the unfolded protein response and glucose and glutamine uptake in endocrine resistant breast cancer.Tyrosine-phosphorylated caveolin-1 (Tyr-14) increases sensitivity to paclitaxel by inhibiting BCL2 and BCLxL proteins via c-Jun N-terminal kinase (JNK).Camptothecin and its analogues: a review on their chemotherapeutic potential.Inhibition of COX-2 in colon cancer modulates tumor growth and MDR-1 expression to enhance tumor regression in therapy-refractory cancers in vivo.Effect of Berry Extracts and Bioactive Compounds on Fulvestrant (ICI 182,780) Sensitive and Resistant Cell LinesActivity of endovesical gemcitabine in BCG-refractory bladder cancer patients: a translational study.Glucose-regulated protein 78 controls cross-talk between apoptosis and autophagy to determine antiestrogen responsivenessTopotecan in the management of cervical cancer.Synergistic growth inhibitory effect of deracoxib with doxorubicin against a canine mammary tumor cell line, CMT-U27Analogs of the novel phytohormone, strigolactone, trigger apoptosis and synergize with PARP inhibitors by inducing DNA damage and inhibiting DNA repair.Cancer therapies utilizing the camptothecins: a review of the in vivo literatureThe synergism between Belotecan and cisplatin in gastric cancer.Efficacy of different sequences of radio- and chemotherapy in experimental models of human melanoma.Enhancement of anticancer efficacy using modified lipophilic nanoparticle drug encapsulation.Organosulfur derivatives of the HDAC inhibitor valproic acid sensitize human lung cancer cell lines to apoptosis and to cisplatin cytotoxicity.Zoledronic acid increases docetaxel cytotoxicity through pMEK and Mcl-1 inhibition in a hormone-sensitive prostate carcinoma cell line.Sensitivity of human multiple myelomas and myeloid leukemias to the proteasome inhibitor I.The apoptogenic response of human myeloid leukaemia cell lines and of normal and malignant haematopoietic progenitor cells to the proteasome inhibitor PSI.Advanced ovarian cancer: phase III randomized study of sequential cisplatin-topotecan and carboplatin-paclitaxel vs carboplatin-paclitaxel.Integrated molecular analysis of Tamoxifen-resistant invasive lobular breast cancer cells identifies MAPK and GRM/mGluR signaling as therapeutic vulnerabilities.EGR1 regulates cellular metabolism and survival in endocrine resistant breast cancer.Suppression of AMF/PGI-mediated tumorigenic activities by ursolic acid in cultured hepatoma cells and in a mouse model.
P2860
Q28364213-F3DCA1C9-3A44-4CE5-8D27-0BE60909B9FDQ30432099-735B3686-0CA8-4790-9395-FC119D7481B2Q33374599-D6E3A0AD-3AD6-4FD2-BC24-4DBD6582985CQ33387996-E317D4CD-4A34-439D-BCBA-2021F54DE804Q33523022-7ABB5591-407C-436A-B01F-4FD0C7CBF93AQ33810548-5635882F-EB7B-4530-8D86-2C6391970534Q34287755-550FFDB9-8365-4C66-A60D-4081D14C8CCBQ34439115-49A3D916-90E2-4D8E-85A0-FFA9ED825ED2Q36006854-25F31EAD-C90E-4358-BFEB-ED91CA342153Q36153120-17390F73-FC09-4D8F-8AB0-3F706CC76AA8Q36172737-D2662588-D98E-4380-ABAA-487953310596Q36546451-F6E9E58D-7D79-43BA-AA9F-8053C4A97FE6Q36610731-A3603439-C6D8-4615-A32C-A22FC8C4EAEAQ36622926-B075ACCE-DCB0-4C06-9F71-721F11EEC632Q36719701-8A45DA97-489C-4E0D-B4C5-5BD5ACC2419EQ36919383-CE049AD6-0E71-4F49-8926-0463332D8C36Q37046504-1D784256-F3A5-4BFC-8CD4-A7D13EBBA1F0Q37069556-29059727-EF0E-4AFD-8F69-AEF7980F0868Q37341744-7783C5A3-BDD8-4A72-A904-B362284D1CE8Q39018908-FC3D496A-A77F-49F0-95F7-71FB317F76F1Q39391640-548B4666-D6B5-4826-B0DC-308E52601935Q39418780-4D2548B3-9E06-491F-AEB5-862CD28AC669Q39952307-10B67DA4-2B39-4A73-ACA9-B76B9752B18BQ40362170-582BA330-836B-4882-A5DC-E1E08444E561Q40809447-844BA18D-88CC-46D2-8E0A-64086920ADF1Q42862031-312EBB30-E2BF-4F64-8A62-9F65E48CFD8AQ46311036-0986A3DE-0404-4803-B251-B01B489339EEQ47122770-11607CAC-92EE-4FB0-9C68-C306E6FB663AQ52624893-D36A46D3-DB1E-4B70-B831-AEE86CFB82E8
P2860
In vitro and in vivo interaction between cisplatin and topotecan in ovarian carcinoma systems.
description
1998 nî lūn-bûn
@nan
1998年の論文
@ja
1998年学术文章
@wuu
1998年学术文章
@zh-cn
1998年学术文章
@zh-hans
1998年学术文章
@zh-my
1998年学术文章
@zh-sg
1998年學術文章
@yue
1998年學術文章
@zh
1998年學術文章
@zh-hant
name
In vitro and in vivo interacti ...... in ovarian carcinoma systems.
@en
type
label
In vitro and in vivo interacti ...... in ovarian carcinoma systems.
@en
prefLabel
In vitro and in vivo interacti ...... in ovarian carcinoma systems.
@en
P2093
P356
P1476
In vitro and in vivo interacti ...... in ovarian carcinoma systems.
@en
P2093
Carenini N
Romanelli S
Tortoreto M
P2888
P304
P356
10.1007/S002800050755
P50
P577
1998-01-01T00:00:00Z
P6179
1031383518